Getting it right on biosimilars and patient safety

By John Horton, President of LegitScript
Oregon Statesman Journal

In just the first three days of summer, at least six unrelated pharmaceutical manufacturers you’ve probably never heard of — companies with names like Xcellerex, Avesthagen, NeuClone and Lupin — were the subject of various press releases. The content varied, but all of the news involved the companies’ plans to refocus their business strategies on a promising new area of medicine: biologics. Read more.

By John Horton, President of LegitScript
Oregon Statesman Journal

Latest News

ASBM Responds to PCMA: Put Patients First, Not PBM Profits

Press Release ARLINGTON, Va., December 9, 2024 (Newswire.com) – As the Senate moves this week to advance passage of the misleadingly named Biosimilar Red Tape Elimination Act (S. 2035), the Alliance for Safe Biologic Medicines (ASBM) reiterates its opposition to the self-interested efforts of the Pharmaceutical Care Management Association (PCMA), which strongly supports this bill that […]

Myth vs Fact: The Biosimilar Red Tape Elimination Act

Click here to download the Myth vs Fact Onepager.

ASBM Physician Survey on Interchangeable Biosimilars Finds Support for Maintaining Current Standards

U.S. Physicians Overwhelmingly Support Current FDA Data Standards, Switching Studies for Interchangeable Biosimilars; Oppose Pharmacy Substitution of Non-Interchangeable Biosimilars FOR IMMEDIATE RELEASE– September 4, 2024 Arlington, VA- U.S. physicians overwhelmingly support maintaining the Food and Drug Administration’s (FDA’s) current data standards for interchangeable biosimilars and oppose treating all biosimilars as interchangeable with the originator biologic […]